Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease.

As a first-line treatment for IgG4-ROD, IV glucocorticoid therapy was well-tolerated, led to better clinical remission and more effectively prevented inflammatory relapse than oral steroids. Further research is needed to establish guidelines on dosage regimens.